Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Proof-of-concept, Randomized, Double-blind, Placebo-controlled, Phase 2a Study to Assess the Prophylactic Antiviral Activity Against Influenza, Safety, Tolerability, and Pharmacokinetics of CD388 Via a Human Viral Challenge Model

Next Previous
Trial Profile

A Proof-of-concept, Randomized, Double-blind, Placebo-controlled, Phase 2a Study to Assess the Prophylactic Antiviral Activity Against Influenza, Safety, Tolerability, and Pharmacokinetics of CD388 Via a Human Viral Challenge Model

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CD 388 (Primary)
  • Indications Influenza virus infections
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Cidara Therapeutics

Most Recent Events

  • 16 Oct 2024 According to a Cidara Therapeutics media release, company announced that the presentations of this trial will be presented at IDWeek 2024 to be held October 16 to 19, 2024 in Los Angeles, CA.
  • 26 Apr 2024 According to a Cidara Therapeutics media release, data from this study will be presented at the 34th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) conference, being held April 27-30, 2024 in Barcelona, Spain.
  • 11 Oct 2023 According to a Cidara Therapeutics media release, additional data from this phase 2a trial will be disclosed at an upcoming conference.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top